AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Pro Medicus Shares Rise Following AU$30 Million Contract with Duly Health and Care
December 23, 2024 10:59 AM AEDT| By Team Kalkine MediaHighlights,AU$30 Million Contract Signed:,Pro Medicus secures a seven-year deal with Duly Health and Care, the largest physician-directed medical group in the U.S. Midwest.,Cloud-Based Imaging Platform Rollout:,The deal includes implementing Pro Medi...
FDA Clears Prescient Therapeutics (ASX:PTX) for Phase 2 PTX-100 Trial Targeting T-Cell Lymphomas
December 23, 2024 12:00 AM AEDT| By Team Kalkine MediaHighlights,Prescient Therapeutics (PTX) receives FDA clearance for a Phase 2 trial of PTX-100.,The trial focuses on relapsed and refractory cutaneous T-cell lymphomas (r/r CTCL).,Phase 1b data showed promising safety and response rates for PTX-100.,P...
Pro Medicus Expands U.S. Presence with $30m Deal
December 23, 2024 12:00 AM AEDT| By Team Kalkine MediaHighlights,Pro Medicus (PME) secures a long-term partnership with Duly Health and Care.,The $30m agreement focuses on implementing advanced cloud imaging solutions.,The new system replaces legacy technologies across DHC's expansive operations.,Pro Me...
Integral Diagnostics Completes Merger with Capitol Health, Appoints New Directors, and Refinances Debt
December 20, 2024 02:28 PM AEDT| By Team Kalkine MediaHighlights,Merger Completion:,Integral Diagnostics (ASX: IDX) has completed its merger with Capitol Health (ASX: CAJ) through a scheme of arrangement.,Scheme Consideration:,Capitol shareholders received 0.12849 Integral shares for each Capitol share...
Little Green Pharma to Acquire Health House Australia for AU$1.25Mn
December 20, 2024 02:14 PM AEDT| By Team Kalkine MediaHighlights,Strategic Acquisition:,Little Green Pharma signs a binding letter of intent to acquire Health House Australia Pty Ltd for $1.25 million.,Revenue Boost:,Health House, a cashflow breakeven business, generates $7.5 million in annual revenue.,...
Radiopharm Theranostics Advances with Phase 1 Cancer Trial Approval
December 20, 2024 01:51 PM AEDT| By Team Kalkine MediaHighlights,Radiopharm,Theranostics,(RAD) secures ethics approval for a Phase 1 cancer trial,.,The trial targets HER2-positive cancers using the novel 177Lu-RAD202 therapy,.,Lutetium-177 isotope aims to deliver localized radiation with minimal side ef...
Radiopharm Theranostics Receives Approval for Lu-RAD202 Clinical Trials
December 20, 2024 12:00 AM AEDT| By Team Kalkine MediaHighlights,Radiopharm Theranostics Ltd (ASX:RAD) has gained ethics approval to commence Phase 1 trials for Lu-RAD202, a candidate treatment for HER2-positive breast and gastric cancers.,The trial will assess the safety and initial clinical activity o...
Mesoblast (ASX:MSB) Gains Momentum with FDA Approval for Ryoncil Therapy
December 19, 2024 06:16 PM AEDT| By Team Kalkine MediaHighlights,FDA approval boosts Mesoblast (MSB) with new therapy Ryoncil.,Ryoncil marks the first approved therapy for SR-aGvHD in the US.,Mesoblast secures strong market positioning for innovative cell therapy.,Biotech company Mesoblast (ASX:MSB) wit...
Mesoblast's (ASX:MSB) Ryoncil Secures Historic FDA Approval for SR-aGvHD
December 19, 2024 03:12 PM AEDT| By Team Kalkine MediaHighlights,Ryoncil,becomes the first FDA-approved mesenchymal stromal cell therapy for SR-,aGvHD,.,Mesoblast (,ASX:MSB,) expands treatment options for children with severe graft-versus-host disease,.,The company to debut on the Nasdaq Biotechnology I...
Breakthrough: Mesoblast (ASX:MSB) Gains FDA Approval for First MSC Therapy in the US
December 19, 2024 01:54 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast (MSB) secures FDA approval for RYONCIL®,.,RYONCIL,becomes,the first mesenchymal stromal cell therapy approved in the US,.,Significant impact,anticipated,for pediatric graft-versus-host disease treatment,.,Mesoblast (ASX:MSB) has...
Austco Healthcare Limited (ASX:AHC): Examining Performance Metrics Amid Market Dynamics
December 19, 2024 12:25 PM AEDT| By Team Kalkine MediaHighlights:,Austco Healthcare Limited (,ASX:AHC,) has a price-to-earnings (P/E) ratio of 13.9x, significantly lower than the broader Australian market average.,The company has shown strong earnings growth, including a 198% gain in the last year and a...
LTR Pharma Partners with Men’s Health Downunder for Erectile Dysfunction Nasal Spray Rollout
December 19, 2024 12:12 PM AEDT| By Team Kalkine MediaHighlights,LTR Pharma partners with MHDU to introduce SPONTAN, a nasal spray for erectile dysfunction.,Collaboration provides access to MHDU’s extensive referral network, including GPs, urologists, and sexual health clinics.,Real-world patient data c...
Mesoblast Shares Surge 33% as FDA Approves Groundbreaking RYONCIL® Therapy
December 19, 2024 12:07 PM AEDT| By Team Kalkine MediaHighlights,FDA approves Mesoblast’s RYONCIL® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy in the U.S.,RYONCIL becomes the only approved treatment for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.,Meso...
Orthocell (ASX:OCC) Advances Nerve Repair Innovation with FDA Submission for Remplir™
December 19, 2024 11:21 AM AEDT| By Team Kalkine MediaHighlights,Orthocell,(OCC),submits,FDA application for,Remplir,™, targeting the expansive US nerve repair market,.,Successful study positions,Remplir,™ as a safe and effective solution for peripheral nerve repair,.,Company prepares for US launch, sup...
Cochlear (ASX:COH) Shares: Why Healthcare Stocks are Attracting Attention
December 18, 2024 01:27 PM AEDT| By Team Kalkine MediaHighlights,Cochlear (COH) focuses on advanced hearing solutions with stable revenue growth,.,The healthcare sector,demonstrates,resilience in challenging economic conditions,.,Cochlear,maintains,steady dividends while expanding its global market pres...
Percheron Therapeutics (ASX:PER) Shares Phase IIb Duchenne Results
December 18, 2024 12:47 PM AEDT| By Team Kalkine MediaHighlights,Percheron Therapeutics (PER) announces Phase IIb trial results of,avicursen,in DMD,.,The trial did not meet its primary efficacy endpoint but confirmed safety and tolerability,.,Further data expected in early 2025 to guide the drug's devel...
Innovative Psilocybin Therapy Shows Promise in Phase 2a IBS Trial
December 18, 2024 12:39 PM AEDT| By Team Kalkine MediaHighlights,Promising interim results for TRP-8802 in IBS trial at Massachusetts General Hospital,.,TRP-8803 highlighted as a potential treatment with advanced delivery benefits,.,Clinical program expands focus to address broader mental health and pai...
Clarity Pharmaceuticals (ASX:CU6) Launches New Cancer Radiopharmaceutical
December 18, 2024 11:30 AM AEDT| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals (CU6) advances a new radiopharmaceutical, SAR-,bisFAP,The product targets multiple cancers with diagnostic and treatment potential,SAR-,bisFAP,demonstrated improved retention and uptake in preclinical trials,Clarity...
Ramsay Health Care (ASX:RHC) Faces Five-Year Decline in Share Price and Earnings
December 18, 2024 11:12 AM AEDT| By Team Kalkine MediaHighlights,Ramsay Health Care (RHC) faces long-term stock decline,.,Earnings per share (EPS) fell annually over the last five years,.,Total shareholder returns were supported by dividends,.,Ramsay Health Care (ASX:RHC), a leading player in the health...
Actinogen Medical (ASX:ACW) Faces Challenges Despite Strong Revenue Growth
December 17, 2024 06:54 PM AEDT| By Team Kalkine MediaHighlights,Actinogen Medical (ACW) shares experienced significant volatility over the past three years.,Revenue growth has been substantial but share price performance remains under pressure.,Insider buying in the last three months signals confidence...
Advertise your brand on Kalkine Media